Published in Circulation on November 02, 2009
Diet as prophylaxis and treatment for venous thromboembolism? Theor Biol Med Model (2010) 0.83
Efficacy of intermittent pneumatic compression for venous thromboembolism prophylaxis in patients undergoing gynecologic surgery: A systematic review and meta-analysis. Oncotarget (2016) 0.75
Venous thromboembolism prophylaxis in hospitalized elderly patients: Time to consider a 'MUST' strategy. J Geriatr Cardiol (2011) 0.75
Prevention of venous thromboembolism in hospitalized acutely ill medical patients: focus on the clinical utility of (low-dose) fondaparinux. Drug Des Devel Ther (2013) 0.75
Perioperative risk factors for death among patients with symptomatic pulmonary thromboembolism. J Anesth (2017) 0.75
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 56.72
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 41.47
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 26.95
Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet (2014) 10.06
Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97
Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med (2014) 6.73
Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE collaboration): a meta-analysis of genome-wide association studies. Lancet Neurol (2012) 3.93
Noninvasive cardiac monitoring for detecting paroxysmal atrial fibrillation or flutter after acute ischemic stroke: a systematic review. Stroke (2007) 3.33
Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation (2004) 2.69
Effect of aspirin on mortality in the primary prevention of cardiovascular disease. Am J Med (2011) 2.65
IScore: a risk score to predict death early after hospitalization for an acute ischemic stroke. Circulation (2011) 2.29
Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet (2009) 2.07
Escalating levels of access to in-hospital care and stroke mortality. Stroke (2008) 1.97
Increased risk of cognitive and functional decline in patients with atrial fibrillation: results of the ONTARGET and TRANSCEND studies. CMAJ (2012) 1.86
Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurol (2012) 1.76
Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials. Circulation (2005) 1.63
Beyond unfractionated heparin and warfarin: current and future advances. Circulation (2007) 1.52
Challenges of establishing new antithrombotic therapies in atrial fibrillation. Circulation (2007) 1.52
Variables associated with 7-day, 30-day, and 1-year fatality after ischemic stroke. Stroke (2008) 1.51
Myocardial injury after noncardiac surgery: a large, international, prospective cohort study establishing diagnostic criteria, characteristics, predictors, and 30-day outcomes. Anesthesiology (2014) 1.47
The prevalence of vertebral fracture on vertebral fracture assessment imaging in a large cohort of patients with rheumatoid arthritis. Rheumatology (Oxford) (2013) 1.46
Pexelizumab does not "complement" percutaneous coronary intervention in patients with ST-elevation myocardial infarction. JAMA (2007) 1.45
Should patients with stroke wear compression stockings to prevent venous thromboembolism? Ann Intern Med (2010) 1.42
Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med (2006) 1.34
Prevalence of cardiovascular risk factors in the Middle East: a systematic review. Eur J Cardiovasc Prev Rehabil (2009) 1.33
Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. Annu Rev Med (2011) 1.26
A diagnostic strategy involving a quantitative latex D-dimer assay reliably excludes deep venous thrombosis. Ann Intern Med (2003) 1.21
Supporting the improvement and management of prescribing for urinary tract infections (SIMPle): protocol for a cluster randomized trial. Trials (2013) 1.19
Albuminuria and decline in cognitive function: The ONTARGET/TRANSCEND studies. Arch Intern Med (2011) 1.14
Periprocedural management and approach to bleeding in patients taking dabigatran. Circulation (2012) 1.14
New anticoagulants. Blood (2004) 1.13
Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. Am Heart J (2010) 1.11
Establishing an optimal therapeutic range for coumarins: filling in the gaps. Arch Intern Med (2004) 1.07
Assessment of anticoagulation intensity and management of bleeding with old and new oral anticoagulants. Can J Cardiol (2013) 1.05
Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. J Stroke Cerebrovasc Dis (2012) 1.05
Tackling the global burden of stroke: the need for large-scale international studies. Lancet Neurol (2009) 1.04
Short-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of prospective studies investigating symptomatic outcomes. Arch Intern Med (2002) 1.04
Reliability of proxy respondents for patients with stroke: a systematic review. J Stroke Cerebrovasc Dis (2010) 1.01
Oral anticoagulants in development: focus on thromboprophylaxis in patients undergoing orthopaedic surgery. Drugs (2006) 1.01
Quantification of risk factors for venous thromboembolism: a preliminary study for the development of a risk assessment tool. Haematologica (2003) 1.00
Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials. Circ Cardiovasc Qual Outcomes (2010) 0.96
Early cerebral small vessel disease and brain volume, cognition, and gait. Ann Neurol (2015) 0.96
An electronic tool for venous thromboembolism prevention in medical and surgical patients. Haematologica (2006) 0.94
New anticoagulants for atrial fibrillation. Semin Thromb Hemost (2009) 0.85
Clinical factors influencing normalization of prothrombin time after stopping warfarin: a retrospective cohort study. Thromb J (2008) 0.84
Thromboprophylaxis practice patterns in two Western Australian teaching hospitals. Haematologica (2004) 0.83
Mild chronic kidney disease and functional impairment in community-dwelling older adults. Age Ageing (2013) 0.81
Graduated compression stockings to prevent venous thromboembolism in hospital: evidence from patients with acute stroke. Pol Arch Med Wewn (2011) 0.78
Randomized controlled trials of new oral anticoagulants for stroke prevention in atrial fibrillation. Curr Opin Cardiol (2012) 0.78
Dietary sodium and cardiovascular disease. Curr Hypertens Rep (2015) 0.77
Possible influence of stroke etiology on hemorrhagic transformation following thrombolysis in warfarin-treated patients. Arch Neurol (2010) 0.75
Sodium and cardiovascular disease. N Engl J Med (2014) 0.75
Using aspirin to prevent cognitive decline. BMJ (2008) 0.75
ESPRIT trial. Lancet (2006) 0.75
Low-molecular-weight heparin as an adjunct to thrombolysis in ST elevation myocardial infarction. Arch Intern Med (2009) 0.75